寡转移性前列腺癌在PSMA PET引导下减瘤性根治性前列腺切除术的结局:一项欧洲多中心研究
这项欧洲13中心研究纳入116例PSMA-PET诊断为原发寡转移性前列腺癌并接受减瘤性根治性前列腺切除术的患者,中位随访27个月,2年去势抵抗-Free生存率85.8%,总生存率98.9%,1年尿控率82%,Clavien-Dindo≥3级并发症5%。作者认为该手术安全可行,但部分患者早期进展风险不可忽视,应考虑多模式治疗。
要点
- 116例PSMA-PET诊断的寡转移性前列腺癌患者接受减瘤性根治性前列腺切除术。
- 2年去势抵抗-Free生存率85.8%(95%CI 78.5-93.7%),总生存率98.9%(95%CI 96.8-100%)。
- Clavien-Dindo≥3级并发症发生率5%,1年尿控率82%。
核心结论
- 对于PSMA-PET诊断的原发寡转移性前列腺癌患者,减瘤性根治性前列腺切除术是一种安全可行的治疗选择。
- 尽管总体肿瘤学结局良好,但部分患者存在不可忽视的早期进展风险,因此应考虑多模式治疗。
研究设计与样本
- 研究为多中心欧洲研究,共纳入13个欧洲中心的116例接受减瘤性根治性前列腺切除术的患者。
- 寡转移性前列腺癌定义为PSMA-PET上miM1a和/或miM1b伴骨转移灶≤5个,和/或miM1c伴肺病灶≤3个。
主要发现
- 95例(82%)为miM1b,18例(16%)为miM1a,3例(2.6%)为miM1c寡转移性前列腺癌。
- 活检前中位前列腺特异性抗原为14 ng/ml,102例(88%)活检分级分组≥3。
- PSMA-PET上中位转移灶数目为2个;38例(33%)、29例(25%)和49例(42%)分别有1个、2个和3个及以上远处阳性病灶。
- 70例(60%)接受新辅助全身治疗,37例(32%)接受转移灶定向治疗。
- 任何并发症和Clavien-Dindo≥3级并发症分别发生于36例(31%)和6例(5%)患者。
关键数值与推荐
- 寡转移性前列腺癌的PSMA-PET定义:miM1a和/或miM1b伴骨转移灶≤5个,和/或miM1c伴肺病灶≤3个。
临床怎么用
- 作者认为,对于PSMA-PET诊断的原发寡转移性前列腺癌患者,减瘤性根治性前列腺切除术是一种安全可行的治疗选择。
- 作者指出,尽管总体肿瘤学结局良好,但部分患者存在不可忽视的早期进展风险,因此应考虑多模式治疗。
局限性
- 局限性包括回顾性设计和短期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: De novo oligometastatic prostate cancer (omPCa) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and its optimal management remains unknown. OBJECTIVE: To analyze the outcomes of patients treated with cytoreductive radical prostatectomy (cRP) for omPCa on PSMA-PET. DESIGN, SETTING, AND PARTICIPANTS: Overall, 116 patients treated with cRP at 13 European centers were identified. Oligometastatic PCa was defined as miM1a and/or miM1b with five or fewer osseous metastases and/or miM1c with three or fewer lung lesions on PSMA-PET. INTERVENTION: Cytoreductive radical prostatectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Thirty-day complications according to Clavien-Dindo, continence rates, time to castration-resistant PCa (CRPC), and overall survival (OS) were analyzed. RESULTS AND LIMITATIONS: Overall, 95 (82%) patients had miM1b, 18 (16%) miM1a, and three (2.6%) miM1c omPCa. The median prebiopsy prostate-specific antigen was 14 ng/ml, and 102 (88%) men had biopsy grade group ≥3 PCa. The median number of metastases on PSMA-PET was 2; 38 (33%), 29 (25%), and 49 (42%) patients had one, two, and three or more distant positive lesions. A total of 70 (60%) men received neoadjuvant systemic therapy, and 37 (32%) underwent metastasis-directed therapy. Any and Clavien-Dindo grade ≥3 complications occurred in 36 (31%) and six (5%) patients, respectively. At a median follow-up of 27 mo, 19 (16%) patients developed CRPC and eight (7%) patients died. The 1-yr urinary continence rate was 82%. The 2-yr CRPC-free survival and OS were 85.8% (95% confidence interval [CI] 78.5-93.7%) and 98.9% (95% CI 96.8-100%), respectively. The limitations include retrospective design and short-term follow-up. CONCLUSIONS: Cytoreductive radical prostatectomy is a safe and feasible treatment option in patients with de novo omPCa on PSMA-PET. Despite overall favorable oncologic outcomes, some of these patients have a non-negligible risk of early progression and thus should be considered for multimodal therapy. PATIENT SUMMARY: We found that patients treated at expert centers with surgery for prostate cancer, with a limited number of metastases detected using novel molecular imaging, have favorable short-term survival, functional results, and acceptable rates of complications.
引用
- Rajwa P, Robesti D, Chaloupka M, et al. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. Eur Urol Oncol. 2023. PMID: 37845121. doi:10.1016/j.euo.2023.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。